Mutations in the genes encoding the cytoplasmic and mitochondrial forms of isocitrate
dehydrogenase (IDH1 and IDH2, respectively; collectively referred to as IDH) are frequently …

Metabolic reprogramming has been widely recognized as a hallmark of malignancy. The
uptake and metabolism of amino acids are aberrantly upregulated in many cancers that …

Background The combination of ivosidenib—an inhibitor of mutant isocitrate dehydrogenase
1 (IDH1)—and azacitidine showed encouraging clinical activity in a phase 1b trial involving …

Summary R-2-hydroxyglutarate (R-2HG), produced at high levels by mutant isocitrate
dehydrogenase 1/2 (IDH1/2) enzymes, was reported as an oncometabolite. We show here …

Recurrent mutations in isocitrate dehydrogenase 2 (IDH2) occur in∼ 12% of patients with
acute myeloid leukemia (AML). Mutated IDH2 proteins neomorphically synthesize 2 …

Background Recent studies have provided a detailed census of genes that are mutated in
acute myeloid leukemia (AML). Our next challenge is to understand how this genetic …

Purpose: To evaluate efficacy and safety of venetoclax+ azacitidine among treatment-naïve
patients with IDH1/2-mutant (mut) acute myeloid leukemia (AML). Patients and Methods …

Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults and the
second most common form of acute leukemia in children. Despite this, very little …

Research into the underlying pathogenic mechanisms of acute myeloid leukemia (AML) has
led to remarkable advances in our understanding of the disease. Mutations now allow us to …

Somatic gain-of-function mutations in isocitrate dehydrogenases (IDH) 1 and 2 are found in
multiple hematologic and solid tumors, leading to accumulation of the oncometabolite (R)-2 …